CrystagenvsIpamorelin

Crystagen is a short Khavinson tripeptide (Glu-Asp-Pro) positioned as the immune and thymus-targeted bioregulator within the wider Khavinson peptide family. The proposed mechanism follows the standard family framework: short peptides interact with gene promoter sequences in thymic and lymphocyte cell nuclei, modulating expression of genes involved in T cell maturation, cytokine production, and broader immune regulation.

Proposed effects include support for thymic function — particularly relevant given the well-documented age-related thymic involution that contributes to immunosenescence in older adults — alongside modulation of lymphocyte chromatin organisation and immune cell maturation pathways. Russian research has reported crystagen-induced improvements in lymphocyte counts, T helper cell function, and clinical recovery from infections in elderly populations and in patients recovering from immunosuppressive treatments. The peptide is often used alongside thymalin (a related thymic peptide preparation also in this database) as part of broader Khavinson immune-support protocols.

As with the rest of the Khavinson family, the efficacy evidence base sits within Russian gerontology and immunology research with limited independent Western validation. Crystagen is not validated as a treatment for primary immunodeficiency, HIV-related immune dysfunction, or other formally diagnosed immune conditions, and should not displace evidence-based immune therapy. The brief plasma half-life (around 30 minutes) reflects the proposed model of transient signalling triggering longer-lasting transcriptional changes in immune cell populations.

Ipamorelin is a pentapeptide growth hormone secretagogue that binds selectively to the growth hormone secretagogue receptor type 1a (GHS-R1a), the same receptor that endogenous ghrelin activates. However, unlike ghrelin and other GHRPs such as GHRP-6 and Hexarelin, ipamorelin demonstrates remarkable selectivity — it stimulates robust GH release while causing minimal elevation of cortisol, prolactin, and ACTH at therapeutic doses.

At the molecular level, ipamorelin binding to GHS-R1a on pituitary somatotrophs activates a Gq/11-coupled signaling cascade that stimulates phospholipase C (PLC), generating inositol trisphosphate (IP3) and diacylglycerol (DAG). IP3 triggers calcium release from intracellular stores, while DAG activates protein kinase C. The resulting rise in intracellular calcium triggers GH vesicle exocytosis. This mechanism is distinct from and synergistic with the cAMP pathway activated by GHRH, which is why combining ipamorelin with a GHRH analogue like CJC-1295 produces amplified GH pulses.

The selectivity of ipamorelin is attributed to its specific binding conformation at the GHS-R1a receptor, which activates the GH release pathway without engaging the broader hypothalamic-pituitary-adrenal axis. It does not significantly activate appetite centers in the hypothalamus at standard doses, nor does it stimulate ACTH release from corticotrophs. This clean side-effect profile has made it the most widely prescribed growth hormone secretagogue in anti-aging and regenerative medicine, often considered the safest starting point for patients new to GH-optimizing peptide therapy.